Verastem, Inc. – LSE:0LOV.L

Add to watchlist

$5.16

+1.36

+35.79%

Market open

Closed in about 2 hours

+14.11%

month

+14.11%

quarter

-54.33%

year

Market Cap	179.35M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-4.4

Revenue	N/A
EBITDA	-101.22M
Income	-105.51M
Revenue Q/Q	N/A
Revenue Y/Y	-95.60%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Verastem, Inc. (LSE:0LOV.L): Profit margin
Jun 2023	0	-24.28M
Sep 2023	0	-20.00M
Dec 2023	114K	-27.36M	-24007.02%
Mar 2024	0	-33.86M

Verastem Financials Estimate

Q Y

Verastem, Inc. (LSE:0LOV.L): Analyst Estimates
Dec 2023	114K	-27.36M	-24007.02%
Mar 2024	0	-33.86M
Oct 2025	1.16M	-25.04M	-2145.33%
Dec 2025	1.73M	-25.49M	-1468.91%

Analysts Price target
Financials & Ratios estimates

Verastem, Inc. (LSE:0LOV.L): Debt to assets
Jun 2023	191758000	69.00M	35.99%
Sep 2023	176153000	71.81M	40.77%
Dec 2023	149718000	71.18M	47.55%
Mar 2024	123539000	77.31M	62.59%

Verastem, Inc. (LSE:0LOV.L): Cash Flow
Jun 2023	-19.90M	14M	91.48M
Sep 2023	-16.58M	-70.07M	-891K
Dec 2023	-29.68M	12.43M	-446K
Mar 2024	-28.30M	30.97M	846K

Verastem alternative data

Verastem, Inc. (LSE:0LOV.L): Employee count
Aug 2023	57
Sep 2023	57
Oct 2023	57
Nov 2023	57
Dec 2023	57
Jan 2024	57
Feb 2024	57
Mar 2024	73
Apr 2024	73
May 2024	73
Jun 2024	73
Jul 2024	73

Status	Patent	Filling date	Issue date
Application	Application THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE Filling date: 25 Nov 2019 Issue date: 22 Oct 2020	25 Nov 2019	22 Oct 2020
Application	Application METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH Filling date: 23 Jul 2019 Issue date: 14 May 2020	23 Jul 2019	14 May 2020
Application	Application COMPOSITIONS AND METHODS FOR TREATMENT OF ABNORMAL CELL GROWTH Filling date: 11 Mar 2019 Issue date: 6 Feb 2020	11 Mar 2019	6 Feb 2020
Grant	Grant Utility: Therapeutic compositions, combinations, and methods of use Filling date: 29 Jun 2016 Issue date: 14 Jan 2020	29 Jun 2016	14 Jan 2020
Grant	Grant Utility: Methods and compositions for treating abnormal cell growth Filling date: 2 Apr 2018 Issue date: 10 Sep 2019	2 Apr 2018	10 Sep 2019

Verastem
Executives

Insider	Age	Compensation
Mr. Brian Stuglik R.Ph., RPh (1959) Chief Executive Officer & Director	66	$890,320
Mr. Daniel W. Paterson (1961) Chief Operating Officer & Pres	64	$679,820
Mr. Robert E. Gagnon (1974) Chief Financial Officer & Chief Bus. Officer	51	$586,640
Ms. Erin S. Cox Senior Director of Investor Relations & Corporation Communications
Mr. Richard H. Aldrich M.B.A., Mba Founder and Consultant
Dr. Robert A. Weinberg nder & Former Chair of Scientific Advisory Board
Dr. Michelle Dipp Co-Founder
Dr. Piyush B. Gupta Ph.D. Co-Founder
Dr. Jonathan Pachter Ph.D. Chief Scientific Officer
Mr. Sean C. Flynn Vice President, Gen. Counsel & Sec.

Frequently Asked Questions (FAQ)

What's the price of Verastem stock today?

One share of Verastem stock can currently be purchased for approximately $5.16.
When is Verastem's next earnings date?

Unfortunately, Verastem's (0LOV.L) next earnings date is currently unknown.
Does Verastem pay dividends?

No, Verastem does not pay dividends.
How much money does Verastem make?

Verastem has a market capitalization of 179.35M.
What is Verastem's stock symbol?

Verastem, Inc. is traded on the LSE under the ticker symbol "0LOV.L".
What is Verastem's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Verastem?

Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Verastem's key executives?
Verastem's management team includes the following people:
- Mr. Brian Stuglik R.Ph., RPh Chief Executive Officer & Director(age: 66, pay: $890,320)
- Mr. Daniel W. Paterson Chief Operating Officer & Pres(age: 64, pay: $679,820)
- Mr. Robert E. Gagnon Chief Financial Officer & Chief Bus. Officer(age: 51, pay: $586,640)
- Ms. Erin S. Cox Senior Director of Investor Relations & Corporation Communications
- Mr. Richard H. Aldrich M.B.A., Mba Founder and Consultant
- Dr. Robert A. Weinberg nder & Former Chair of Scientific Advisory Board
- Dr. Michelle Dipp Co-Founder
- Dr. Piyush B. Gupta Ph.D. Co-Founder
- Dr. Jonathan Pachter Ph.D. Chief Scientific Officer
- Mr. Sean C. Flynn Vice President, Gen. Counsel & Sec.
Is Verastem founder-led company?

Yes, Verastem is a company led by its founders Mr. Richard H. Aldrich M.B.A., Mba, Dr. Michelle Dipp and Dr. Piyush B. Gupta Ph.D..
How many employees does Verastem have?

As Jul 2024, Verastem employs 73 workers.
When Verastem went public?

Verastem, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
What is Verastem's official website?

The official website for Verastem is verastem.com.
Where are Verastem's headquarters?

Verastem is headquartered at 117 Kendrick Street, Needham, MA.
How can i contact Verastem?

Verastem's mailing address is 117 Kendrick Street, Needham, MA and company can be reached via phone at +7 812924200.

Verastem, Inc.

verastem.com

Exchange:

LSE

Full time employees:

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

+7 812924200

117 Kendrick Street
Needham, MA 02494

:
ISIN: US92337C2035
CUSIP: 92337C203